Hypha Labs Shifts to Mushroom Tech, Reports Zero Revenue Amid Rising Losses
Ticker: FUNI · Form: 10-Q · Filed: Aug 21, 2025 · CIK: 1502966
Sentiment: bearish
Topics: Biotechnology, Startup, Zero Revenue, High Burn Rate, Product Development, Cannabis Exit, Functional Mushrooms
TL;DR
**FUNI is a pure R&D play with no revenue, betting big on a mushroom device; avoid until they prove market viability.**
AI Summary
Hypha Labs, Inc. (FUNI) reported no revenue for the three and nine months ended June 30, 2025, a significant shift from its previous cannabis testing business. The company's net loss from continuing operations widened to $2,543,486 for the nine months ended June 30, 2025, compared to a net loss of $904,586 in the prior year, primarily due to increased operating expenses. General and administrative expenses rose to $1,172,261 for the nine months ended June 30, 2025, up from $683,456, and professional fees surged to $1,338,192 from $574,728. Cash decreased from $91,166 on September 30, 2024, to $147,192 on June 30, 2025, reflecting a net increase of $56,026, largely due to financing activities. The company is transitioning to the research, development, and commercialization of the Hypha Micropearl accelerator, a home appliance for mushroom production, with a goal to market it by the end of calendar year 2025. Total liabilities increased substantially to $2,186,704 as of June 30, 2025, from $1,420,498 on September 30, 2024, driven by a rise in accounts payable and current maturities of notes and convertible notes payable.
Why It Matters
This filing signals a complete pivot for Hypha Labs, moving from cannabis testing to a speculative home mushroom cultivation device. For investors, this means a high-risk, high-reward scenario, as the company has no current revenue stream and is burning cash on R&D and professional fees. Employees from the former Digipath Labs business are likely impacted by the asset sale, while new hires would be focused on the Hypha Micropearl accelerator. Customers of the former cannabis testing lab are no longer served by Hypha Labs. The broader market will watch if this innovative, yet unproven, 'Micropearl accelerator' can carve out a niche in the functional food and home appliance sectors, potentially disrupting traditional mushroom production methods, but it faces significant competitive hurdles from established players in both consumer electronics and health supplements.
Risk Assessment
Risk Level: high — The company reported no revenues for the three and nine months ended June 30, 2025, indicating a complete lack of operational income. Its accumulated deficit reached $23,090,912 as of June 30, 2025, and total liabilities surged to $2,186,704, significantly exceeding its total assets of $454,103, demonstrating severe financial distress and reliance on financing for survival.
Analyst Insight
Investors should exercise extreme caution and consider this a highly speculative investment. Given the lack of revenue, increasing losses, and significant liabilities, it would be prudent to wait for concrete evidence of market acceptance and commercialization success for the Hypha Micropearl accelerator before considering any investment.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $0
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- $2,186,704
- net Income
- N/A
- eps
- N/A
- gross Margin
- N/A
- cash Position
- $147,192
- revenue Growth
- -100.0%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Continuing Operations (Cannabis Testing) | $0 | -100.0% |
| New Business (Hypha Micropearl) | $0 | N/A |
Key Numbers
- $0 — Revenue (No revenue for the three and nine months ended June 30, 2025, indicating a complete operational shift.)
- $(2,543,486) — Net Loss from Continuing Operations (Increased from $(904,586) in 2024, reflecting higher operating expenses.)
- $1,172,261 — General and Administrative Expenses (Increased from $683,456 for the nine months ended June 30, 2024, contributing to wider losses.)
- $1,338,192 — Professional Fees (Significantly increased from $574,728 for the nine months ended June 30, 2024, indicating higher legal/consulting costs.)
- $147,192 — Cash (As of June 30, 2025, a slight increase from $91,166 on September 30, 2024, primarily from financing activities.)
- $2,186,704 — Total Current Liabilities (Increased from $1,393,660 on September 30, 2024, driven by notes payable and accounts payable.)
- $23,090,912 — Accumulated Deficit (Widened from $20,547,426 on September 30, 2024, reflecting ongoing losses.)
- 145,121,825 — Common Shares Outstanding (As of August 21, 2025, an increase from 123,046,825 on September 30, 2024, due to stock-based compensation.)
- $1,208,235 — Current Maturities of Convertible Notes Payable (Increased from $1,078,235 on September 30, 2024, adding to short-term debt burden.)
- 8 days — Micropearl Production Time (The time it takes for the Hypha Micropearl accelerator to produce enriched mycelium.)
Key Players & Entities
- Hypha Labs, Inc. (company) — Parent company, formerly Digipath, Inc.
- Digipath Labs, Inc. (company) — Wholly-owned subsidiary whose net assets were sold on February 20, 2024
- Hypha Products Inc. (company) — Wholly-owned subsidiary formed to develop the Hypha Micropearl accelerator
- DPL NV, LLC (company) — Buyer of Digipath Labs' net assets
- $2,543,486 (dollar_amount) — Net loss from continuing operations for the nine months ended June 30, 2025
- $0 (dollar_amount) — Revenue for the three and nine months ended June 30, 2025
- $2,186,704 (dollar_amount) — Total current liabilities as of June 30, 2025
- $454,103 (dollar_amount) — Total Assets as of June 30, 2025
- $23,090,912 (dollar_amount) — Accumulated deficit as of June 30, 2025
- Nevada (regulator) — State of incorporation for Hypha Labs, Inc.
FAQ
What is Hypha Labs, Inc.'s current business focus after selling Digipath Labs?
After selling Digipath Labs, Inc. on February 20, 2024, Hypha Labs, Inc. is now focused on the research, development, and commercialization of the Hypha Micropearl accelerator, a home appliance designed to accelerate the production of nutritionally beneficial mushrooms for human consumption.
How much revenue did Hypha Labs, Inc. generate for the nine months ended June 30, 2025?
Hypha Labs, Inc. generated no revenue for the three and nine months ended June 30, 2025, marking a complete absence of sales from its continuing operations.
What was Hypha Labs, Inc.'s net loss for the nine months ended June 30, 2025?
Hypha Labs, Inc. reported a net loss from continuing operations of $2,543,486 for the nine months ended June 30, 2025, which is a significant increase from the $904,586 net loss in the same period of 2024.
How have Hypha Labs, Inc.'s operating expenses changed year-over-year?
For the nine months ended June 30, 2025, total operating expenses for Hypha Labs, Inc. increased to $2,510,453, up from $1,258,184 in the prior year. This was driven by general and administrative expenses rising to $1,172,261 and professional fees surging to $1,338,192.
What is the financial position of Hypha Labs, Inc. as of June 30, 2025?
As of June 30, 2025, Hypha Labs, Inc. had total assets of $454,103 and total liabilities of $2,186,704. The company also reported an accumulated deficit of $23,090,912, indicating a negative stockholders' deficit of $2,066,201.
What are the key risks associated with Hypha Labs, Inc.'s new business model?
Key risks include the uncertainty of successfully designing, developing, and testing the Hypha Micropearl accelerator, securing a manufacturing arrangement, and achieving commercial sale by the end of calendar year 2025, or at all. The company currently has no revenue and a substantial accumulated deficit.
How much cash did Hypha Labs, Inc. have at the end of the quarter?
As of June 30, 2025, Hypha Labs, Inc. had cash of $147,192, an increase from $91,166 at September 30, 2024, primarily due to proceeds from notes and convertible notes payable.
What is the status of Hypha Labs, Inc.'s commercialization goal for the Micropearl accelerator?
Hypha Labs, Inc. intends to continue the design, development, and testing of the Hypha Micropearl accelerator over the next six months, with a goal to market the product by the end of calendar year 2025. However, there is no assurance this goal will be achieved.
Did Hypha Labs, Inc. issue any new shares during the period?
Yes, Hypha Labs, Inc. issued 8,500,000 common shares for stock-based compensation during the three months ended June 30, 2025, and 1,000 shares of Series C preferred stock for $1 during the nine months ended June 30, 2025.
What was the impact of discontinued operations on Hypha Labs, Inc.'s financial results?
For the nine months ended June 30, 2024, discontinued operations contributed net income of $585,156 and provided $373,913 in cash from operating activities. However, for the nine months ended June 30, 2025, there was no income or cash flow from discontinued operations, as the asset sale was completed in February 2024.
Risk Factors
- Significant Increase in Operating Expenses [high — financial]: Operating expenses, particularly G&A and professional fees, surged by $1,172,261 and $1,338,192 respectively for the nine months ended June 30, 2025. This led to a widened net loss from continuing operations of $2,543,486, up from $904,586 in the prior year, indicating a substantial burn rate.
- Growing Debt Load [high — financial]: Total liabilities increased to $2,186,704 as of June 30, 2025, from $1,420,498 on September 30, 2024. This increase is driven by higher accounts payable and significant increases in notes and convertible notes payable, including current maturities of $1,208,235.
- Dependence on New Product Commercialization [high — operational]: The company's future success hinges entirely on the successful research, development, and commercialization of the Hypha Micropearl accelerator. Any delays or failures in bringing this product to market by the end of calendar year 2025 could severely impact the company's viability.
- Unproven Market for Hypha Micropearl [medium — market]: The market acceptance and demand for a home appliance for mushroom production (Hypha Micropearl) are unproven. The company faces the risk of insufficient customer adoption, competition from existing or new entrants, and challenges in scaling production and distribution.
- Limited Cash Reserves [medium — financial]: While cash increased to $147,192 as of June 30, 2025, this is primarily due to financing activities. The company's substantial operating losses and increasing liabilities suggest a continued need for external funding, posing a risk of dilution or inability to meet obligations.
- Transition from Regulated Industry [low — legal]: The company has transitioned away from the cannabis testing business. While this may reduce direct regulatory burdens, any residual liabilities or reputational issues from the prior business could persist. The new venture may also face unforeseen regulatory hurdles.
Industry Context
The home appliance market for food production is an emerging sector. Hypha Labs is attempting to carve out a niche with its Hypha Micropearl accelerator for mushroom cultivation. This market is characterized by innovation and a growing consumer interest in home-grown food, but also faces challenges in consumer education and adoption of new technologies.
Regulatory Implications
Having exited the highly regulated cannabis testing industry, Hypha Labs may face fewer direct regulatory hurdles with its new venture. However, any new product in the consumer appliance or food production space could be subject to safety, labeling, and environmental regulations that need careful navigation.
What Investors Should Do
- Monitor the development and launch timeline of the Hypha Micropearl accelerator closely; any delays increase financial risk.
- Analyze future funding rounds, as the company's cash burn rate and increasing liabilities suggest a continued need for capital, potentially leading to dilution.
- Assess market reception and competitive landscape for the Hypha Micropearl upon its launch to gauge revenue potential.
- Evaluate the company's ability to manage its escalating operating expenses, particularly professional fees, to improve future profitability.
Key Dates
- 2025-06-30: End of Nine Months Reporting Period — Reported $0 revenue and a net loss of $2,543,486, with total liabilities at $2,186,704.
- 2025-12-31: Target for Hypha Micropearl Market Launch — Critical deadline for the company's new product commercialization strategy; failure to meet could significantly impact future prospects.
- 2024-09-30: Prior Fiscal Year End — Provided a baseline for comparison, showing total liabilities of $1,420,498 and a net loss from continuing operations of $904,586 for the prior nine-month period.
Glossary
- Continuing Operations
- Refers to the ongoing business activities of a company that are expected to continue indefinitely. Discontinued operations are reported separately. (Hypha Labs has ceased its cannabis testing business, which is now considered discontinued, and is focusing on its new venture as continuing operations.)
- Accumulated Deficit
- The cumulative net losses of a company since its inception, less any net gains. It represents a deficit in stockholders' equity. (Hypha Labs has an accumulated deficit of $23,090,912 as of June 30, 2025, highlighting its history of unprofitability.)
- Convertible Notes Payable
- Debt instruments that can be converted into a predetermined amount of the issuer's equity at the option of the holder. (An increase in convertible notes payable contributes to Hypha Labs' rising total liabilities and potential future equity dilution.)
- Stock-Based Compensation
- Compensation provided to employees in the form of stock options or shares, rather than cash. (This is cited as a reason for the increase in common shares outstanding, potentially diluting existing shareholders.)
- Mycelium
- The vegetative part of a fungus, consisting of a network of fine white filaments (hyphae). (The Hypha Micropearl accelerator is designed for mushroom production, which involves cultivating mycelium.)
Year-Over-Year Comparison
Compared to the prior year's nine-month period, Hypha Labs has seen a complete collapse in revenue from its previous cannabis testing business, reporting $0. This has been accompanied by a significant increase in net loss from continuing operations, widening from $904,586 to $2,543,486, driven by a substantial rise in general and administrative expenses and professional fees. Total liabilities have also grown considerably, indicating increased financial pressure.
Filing Stats: 4,605 words · 18 min read · ~15 pages · Grade level 15.1 · Accepted 2025-08-21 16:06:03
Filing Documents
- form10-q.htm (10-Q) — 1440KB
- ex31-1.htm (EX-31.1) — 19KB
- ex32-1.htm (EX-32.1) — 8KB
- form10-q_001.jpg (GRAPHIC) — 16KB
- 0001641172-25-025082.txt ( ) — 7253KB
- funi-20250630.xsd (EX-101.SCH) — 49KB
- funi-20250630_cal.xml (EX-101.CAL) — 68KB
- funi-20250630_def.xml (EX-101.DEF) — 200KB
- funi-20250630_lab.xml (EX-101.LAB) — 441KB
- funi-20250630_pre.xml (EX-101.PRE) — 351KB
- form10-q_htm.xml (XML) — 1295KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION 3 ITEM 1.
FINANCIAL STATEMENTS (Unaudited)
FINANCIAL STATEMENTS (Unaudited) 3 Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and September 30, 2024 3 Consolidated Statements of Operations for the Three and Nine Months Ended June 30, 2025 and 2024 (Unaudited) 4 Consolidated Statements of Stockholders' Deficit for the Three and Nine Months Ended June 30, 2025 and 2024 (Unaudited) 5 Consolidated Statements of Cash Flows for the Nine Months Ended June 30, 2025 and 2024 (Unaudited) 6 Notes to the Consolidated Financial Statements (Unaudited) 7 ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 21 ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 25 ITEM 4.
CONTROLS AND PROCEDURES
CONTROLS AND PROCEDURES 25
- OTHER INFORMATION
PART II - OTHER INFORMATION 26 ITEM 1.
Legal Proceedings
Legal Proceedings 26 ITEM 1A.
RISK FACTORS
RISK FACTORS 26 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 26 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 26 ITEM 4. MINE SAFETY DISCLOSURES 26 ITEM 5. OTHER INFORMATION 26 ITEM 6. EXHIBITS 27
SIGNATURES
SIGNATURES 28 2 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS . HYPHA LABS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS June 30, 2025 September 30, 2024 (Unaudited) Assets Current assets: Cash $ 147,192 $ 91,166 Prepaids and other current assets 40,156 289,024 Deferred offering costs 153,032 30,000 Total current assets 340,380 410,190 Fixed assets, net 78,083 26,609 Right-of-use asset 35,640 57,006 Total non-current assets 113,723 83,615 Total Assets $ 454,103 $ 493,805 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 383,256 $ 86,348 Accrued expenses 223,034 166,726 Accrued expenses – related parties 59,901 25,923 Accrued expenses 59,901 25,923 Current maturities of notes payable 275,733 - Current maturities of convertible notes payable, net of discounts 1,208,235 1,078,235 Lease liability – current 36,545 36,428 Total current liabilities 2,186,704 1,393,660 Non-current liabilities: Lease liability - long term - 26,838 Total non-current liabilities - 26,838 Total Liabilities 2,186,704 1,420,498 Series B convertible preferred stock, $ 0.001 par value, 1,500,000 shares authorized; 333,600 shares issued and outstanding as of June 30, 2025 and September 30, 2024 333,600 333,600 Commitments and Contingencies - - Stockholders' Deficit: Series A convertible preferred stock, $ 0.001 par value, 6,000,000 shares authorized; 1,047,942 shares issued and outstanding as of June 30, 2025 and September 30, 2024 1,048 1,048 Series C preferred stock, $ 0.001 par value, 1,000 shares authorized; 1,000 and no shares issued and outstanding as of June 30, 2025 and September 30, 2024, respectively 1 - Series D preferred stock, $ 0.001 par value, 60,000,000 shares authorized; no shares issued and outstanding as of June 30, 2025 and September 30, 2024, respectively - - Preferred stock, value - - Common stock, $ 0.0